Patents Assigned to Board of Regents of the University of Texas System
  • Patent number: 10774637
    Abstract: Systems and methods are disclosed that provide highly accurate and controllable measurements of rock formation properties in a wellbore. The systems and methods utilize a prescribed input signal to mechanically perturb a drill string in contact with a rock formation in order to elicit a mechanical response. Based on the input signal and the mechanical response, a transfer function is computed and analyzed, wherein the analysis uses estimates of the drill string resonances to identify rock formation resonances, which are used, in turn, to determine the rock formation properties.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 15, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Carlos Torres-Verdin, Roman Shor, Eric van Oort
  • Patent number: 10773212
    Abstract: A method of recovering one or more insoluble oils from a liquid source using one or more membrane or membrane contactors, comprising the steps of: pumping the liquid source comprising the one or more oils to the membranes or membrane contactors, contacting the liquid source with a first surface of the membrane or membrane contactors, coalescing the one or more oils within the liquid source onto the first surface of the membrane contactors, pumping one or more recovery fluids through the membrane or membrane contactors in contact with the second surface of the membrane or membrane contactors, and removing a first stream of oil coalesced from the second surface of the membranes or membrane contactors.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 15, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Frank Seibert, Stacy S. Truscott, Stephen William Briggs, Peter B. Kipp
  • Patent number: 10772913
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Publication number: 20200283002
    Abstract: Embodiments of the present systems and methods may provide techniques that provide dynamic groups and attribute-based access control (ABAC) model (referred as CV-ABACG) to secure communication, data exchange and resource access in smart vehicles ecosystems. In embodiments, the model not only considers system wide attributes-based security policies, but also takes into account individual user privacy preferences for allowing or denying service notifications, alerts, and operations to on-board resources. Embodiments of the present systems and methods may provide groups in vehicular IoT, which may be dynamically assigned to moving entities like connected cars, based on their current GPS coordinates, speed or other attributes, to ensure relevance of location and time sensitive notification services, to provide administrative benefits to manage large numbers of entities, and to enable attributes inheritance for fine-grained authorization policies.
    Type: Application
    Filed: March 6, 2020
    Publication date: September 10, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Maanak GUPTA, James BENSON, Farhan PATWA, Ravinderpal SANDHU
  • Publication number: 20200284803
    Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
    Type: Application
    Filed: February 19, 2018
    Publication date: September 10, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David E. GERBER, Edward WAKELAND, Quan LI, Saad KHAN, Jason Y. PARK, Xin LUO, Yang XIE
  • Publication number: 20200283768
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 10, 2020
    Applicants: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. GELLER, David GREENBERG
  • Patent number: 10765745
    Abstract: In one aspect, compositions comprising a population of core-shell nanoparticles are described herein. In some cases, the population of core-shell nanoparticles comprises a core component and a shell component encapsulating or surrounding the core component. Additionally, one or more radiosensitizers are disposed in or dispersed throughout the core component, or an interior region of the core component. Similarly, one or more chemotherapeutic agents are disposed in or dispersed throughout the shell component, or an interior region of the shell component. Moreover, in some cases, the core component is formed from one or more biodegradable polymers. Further, in some instances, the shell component is formed from one or more stimuli responsive polymers, such as a temperature-responsive polymer and/or pH-responsive polymer.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, the University of Texas System
    Inventors: Kytai Nguyen, Jyothi Menon, Debabrata Saha
  • Patent number: 10767179
    Abstract: Certain embodiments are directed to methods of identifying neuroblastoma differentiation-inducing compounds or agent and their use in treating neuroblastoma.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: September 8, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Liqin Du
  • Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20200275641
    Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, a “humanized” mouse model is provided that can be used to test a variety of DMD exon skipping strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 44 deletion via CRISPR-mediated exon skipping in the humanized mouse model, in patient-derived iPS cells and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.
    Type: Application
    Filed: May 13, 2020
    Publication date: September 3, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Yi-Li MIN, Rhonda BASSEL-DUBY, Eric OLSON
  • Patent number: 10759833
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 1, 2020
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Steven J. Norris
  • Patent number: 10758121
    Abstract: Embodiments of the present invention comprises apparatuses and methods of measuring levels of neurological impairment. Certain embodiments of the invention comprise a headset that emits light into the user's eyes and the system tracks the pupils' orientation, movement, contraction and dilation. In specific embodiments, the headset can run a battery of tests and calculate a score indicating the user's level of neurological impairment.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 1, 2020
    Assignees: Board of Regents, The University of Texas System, University of Iowa Research Foundation
    Inventors: Robert Rennaker, Elliot Frohman, Randy Kardon
  • Publication number: 20200268801
    Abstract: A high-throughput screening system is provided for optimizing the conditioning of patient-specific mesenchymal stem cells using a combinatorial set of biochemical factors, pharmacological inhibitors, and biomechanical forces. Also provided are generalized conditions for performing such conditioning. Cells made by these methods are also provided, in addition to cells having a mixed N endothelial cell/pericyte phenotype. These cells produce angiogenic growth factors and induce vascularization following implantation.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 27, 2020
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Aaron B. BAKER, Jason LEE
  • Publication number: 20200271674
    Abstract: Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased.
    Type: Application
    Filed: March 25, 2020
    Publication date: August 27, 2020
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Donald R. Royall, Raymond F. Palmer
  • Patent number: 10755817
    Abstract: A system for predicting medical events and conditions that are reflected in gait may include a data capture subsystem configured to capture data pertaining to a position and/or motion of a patient, a data analysis and outcome generation subsystem configured to analyze the captured data and to generate output pertaining to a likelihood of the patient experiencing a medical event or medical condition, and a user interface subsystem configured to provide the output to a user, e.g., healthcare provider, and to receive feedback from the user. Methods for predicting medical events and conditions reflected in gait are also provided.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 25, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gian-Luca Mariottini, Aaron N. Staranowicz, Christopher T. Ray
  • Patent number: 10750947
    Abstract: A system and method for intraoperative fluorescence imaging. A system for intraoperative fluorescence imaging includes a visible light source, a laser light source, a visible light image detector, a fluorescence image detector, radio frequency (RF) circuitry, and an image processing system. The RF circuitry is coupled to the laser light source and the fluorescence image detector. The RF circuitry is configured to modulate laser light generated by the laser source, and modulate an intensifier of the fluorescence image detector. The image processing system is coupled to the visible light image detector and the fluorescence image detector. The image processing system is configured to merge a fluorescence image produced by the fluorescence image detector and a visible light image produced by the visible light image detector to generate an intraoperative image showing an outline of a region of interest identified in the fluorescence image overlaid on the visible light image.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 25, 2020
    Assignee: Board of Regents of the University of Texas System
    Inventors: Banghe Zhu, Eva M. Sevick-Muraca, John C. Rasmussen
  • Patent number: 10751416
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 25, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller
  • Patent number: 10750990
    Abstract: The present invention comprises apparatuses and methods of detecting impacts to the head. Accelerometers attached to a user's head and neck or body is used to measure the differential acceleration of the head with respect to the neck or body. A differential acceleration exceeding a certain threshold may be indicative of the user suffering a traumatic brain injury.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 25, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventor: Robert Rennaker
  • Patent number: 10751348
    Abstract: The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 25, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDCARA PHARMACEUTICALS, LLC
    Inventors: Robert A. Josephs, Craig Herman
  • Patent number: 10751409
    Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: August 25, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Stephen Clay Schafer